Patrys

Market Announcements 2018

OCTOBER 2018

25 October 2018 – Settlement of Manufacturing Claims

23 October 2018 – Notice of Annual General Meeting/ Proxy Form

8 October 2018 – Patrys and Yale Awarded Grant

4 October 2018 – PAT-DX1 Clinical Target Indications Confirmed

SEPTEMBER 2018

13 September 2018 – PAB Business Review – 30 June 2018

AUGUST 2018

28 August 2018 – Patrys and WEHI Awarded Grant

1 August 2018 – Patent Granted for Pre-clinical IgM Candidate PAT-LM1

JULY 2018

5 July 2018 – Preliminary PAT-DX1 Pharmacokinetics

3 July 2018 – China and Japan Both Grant Patents for Deoxymab 3E10

JUNE 2018

12 June 2018 – Corporate Overview

MAY 2018

31 May 2018 – PAT-DX1 Targets and Kills Brain Cancer Stem Cells

21 May 2018 – Patrys Increases Capital Raising to $4.6 Million

17 May 2018 – New Pre-Clinical Collaboration on PAT-DX1

16 May 2018 – Announcement of $3.5 Million Share Placement

10 May 2018 – Investor Update

APRIL 2018

17 April 2018 – Patrys Presents at AACR Conference

MARCH 2018

19 March 2018 – PAT-DX1 Improves Survival in Animal Model of Glioblastoma

FEBRUARY 2018

28 February 2018 – PAT-DX1 Crosses the Blood Brain Barrier to Reduce Tumor Size

16 February 2018 – Patrys Successfully Completes Rights Issue – Raises $2.4M

JANUARY 2018

30 January 2018 – Publication and Patent Filing for Humanized Version of Deoxymab 3E10

29 January 2018 – PAT-DX1-NP  Localizes to Lymph Node Metastases

29 January 2018 – PAT-DX1 Targets Delivery of Nanoparticles to Breast Cancer

15 January 2018 – Corporate Overview

15 January 2018 – $2.4M Fully Underwritten Rights Issue